PEP-CMV
Phase 1Active 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Medulloblastoma
Conditions
Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma
Trial Timeline
Jun 29, 2018 → Apr 1, 2026
NCT ID
NCT03299309About PEP-CMV
PEP-CMV is a phase 1 stage product being developed by Brain Biotech for Recurrent Medulloblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT03299309. Target conditions include Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03299309 | Phase 1 | Active |
Competing Products
20 competing products in Recurrent Medulloblastoma